PHILADELPHIA (December 11, 2023) — Fox Chase Cancer Center and Fels Cancer Institute for Personalized Medicine researchers will participate in the presentation of six research projects at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held in San Diego, California December 9-12.
Saturday, December 9
120: Clonal Targeting of DNA Damage Response Pathways Eradicates Myeloproliferative Neoplasms: Monika Toma, PhD; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine at Temple University; Program: Oral and Poster Abstracts; Session: 802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders; Saturday, December 9, 2023: 9:30 AM-11:00 AM; Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina).
Sunday, December 10
580: Inactivation of DNA Polymerase Theta (Polθ) is Synthetic Lethal in DNMT3A Mutated Myeloid Malignancies – Potential Clinical Applications: Bac Viet Le, PhD, Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine; Program: Oral and Poster Abstracts; Session: 602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells; Sunday, December 10, 2023: 4:30 PM-6:00 PM; Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina).
3772: Use of Prephase Steroids in Older Patients Treated for Diffuse Large B-Cell Lymphoma: Alexander Vartanov, MD, Fox Chase Cancer Center; Program: Oral and Poster Abstracts; Session: 905. Outcomes Research in Lymphoid Malignancies: Poster II; Sunday, December 10, 2023: 6:00 PM-8:00 PM; Halls G-H (San Diego Convention Center).
3333: Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the MagnetisMM Studies: Asya Varshavsky-Yanovsky, MD, PhD, Fox Chase Cancer Center; Program: Oral and Poster Abstracts, Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II; Sunday, December 10, 2023: 6:00 PM-8:00 PM; Halls G-H (San Diego Convention Center).
Monday, December 11
996: Divergent Functions of ERK2 Substrate Binding Modalities in Myeloproliferative Neoplasm: Billy Truong, Fox Chase Cancer Center; Program: Oral and Poster Abstracts; Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Oncogenic Drivers and Genetic Models; Monday, December 11, 2023: 4:30 PM – 6:00 PM; Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina).
4301: Clonal Medicine Targeting DNA Damage Response Eradicates AML: Monika Toma, PhD; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine; Program: Oral and Poster Abstracts; Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III; Monday, December 11, 2023: 6:00 PM-8:00 PM; Halls G-H (San Diego Convention Center).